This phosphorylation prevents GSK3β from binding to GLI1 and β-catenin, leading to the inhibition of degradation and the increased expression of GLI1 and β-catenin in melanoma (Figure 2l) [97]. The gene discussed is GLI1; the disease is melanoma.